Loading stock data…
Zevra Therapeutics (ZVRA)
$9.53-3.00 (-23.92%)
Market ClosedLast close Jul 24
Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Zevra Therapeutics, Inc. in the Healthcare sector is trading at $9.53 with a market capitalization of $738M. Wall Street consensus targets $26.33 (9 analysts), implying a +176.5% move over the next 12 months. The stock is currently 37% below its 52-week high of $15.04, remaining 6.0% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality. Risk note: RSI 21 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +176.5% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 21) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $36.22M↑ | $34.13M↑ | $26.06M↑ | $25.88M↑ | $20.40M |
| Gross Profit | $34.32M↑ | $32.60M↑ | $24.82M↑ | $13.50M↓ | $19.06M |
| Operating Income | $8.83M↓ | $9.31M↑ | $4.14M↑ | -$12.33M↓ | -$5.36M |
| Net Income | $37.89M↑ | $12.16M↑ | -$544,000↓ | $74.71M↑ | -$3.10M |
Peer Comparison
JNJUNHPFE
Fundamentals
Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidat...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$737.76M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
60.36%
Volume
Today's trading volume
6.92M
Recent News
ZVRA Stock Sinks 23% On EU Setback — Analyst Says Risk Is ‘A Headwind, But Not Insurmountable’
On Friday, Zevra announced that the EMA’s Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion on its application to market arimoclomol for Niemann-Pick disease type C.
Zevra Therapeutics Receives EMA Negative Opinion on Arimoclomol Marketing Application
The company plans to seek a re-examination after the European regulator’s advisory committee issued a negative opinion on arimoclomol for Niemann-Pick disease type C. Key Investor TakeawaysZevra Therapeutics (NASDAQ:ZVRA) received a negative CHMP opinion on the European Marketing Authorization Application for arimoclomol.
ZVRA Stock Plummets Pre-Market, Heads For Worst Day In Over 5 Years – What’s Driving The Sell-Off?
The European Medicines Agency recommended refusal of the marketing authorization for Zevra’s Meplyffa, a medicine intended for the treatment of Niemann-Pick disease type C.
Is Zevra Therapeutics (ZVRA) Using MIPLYFFA Patent Extensions To Deepen Its Rare-Disease Moat?
Zevra Therapeutics recently submitted U.S. Patent No. 11,707,456 for its approved Niemann-Pick type C treatment MIPLYFFA to the FDA’s Orange Book, aiming to secure patent protection until 2041 and reinforce barriers to generic competition. This move strengthens Zevra’s intellectual property position around its only FDA-approved medicine, potentially extending the period during which it can exclusively commercialize MIPLYFFA. We’ll now examine how this extended MIPLYFFA patent protection to...
ZVRA Stock Hits Its Highest Levels In Nearly 5 Years – What’s Driving This Sharp Rally Today?
Zevra Therapeutics shares saw a series of positive brokerage actions after the company asked the U.S. Food and Drug Administration to add a new patent for its Miplyffa drug to the Orange Book.